Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
11
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 11 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Omeprazole Omeprazole | D | $367M | -13% | 7,509,766 | $49 | $0.17 |
| Esomeprazole Magnesium Esomeprazole Magnesium | D | $124M | -28% | 741,842 | $168 | $0.64 |
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | D | $122M | -30% | 18,255 | $6,704 | $28.61 |
| Nexium Esomeprazole Magnesium | D | $59.7M | -20% | 20,438 | $2,922 | $8.85 |
| Naproxen-Esomeprazole Mag Naproxen/Esomeprazole Mag | D | $15.9M | -40% | 3,550 | $4,481 | $14.55 |
| Konvomep Omeprazole/Sodium Bicarbonate | D | $4.5M | +133% | 1,959 | $2,280 | $1.41 |
| Zegerid Omeprazole/Sodium Bicarbonate | D | $3.3M | -62% | 252 | $12,949 | $105.22 |
| Prilosec Omeprazole Magnesium | D | $3.2M | 0% | 823 | $3,928 | $15.25 |
| Talicia Omeprazole/Amoxicill/Rifabutin | D | $2.6M | -21% | 3,265 | $802 | $4.68 |
| Vimovo Naproxen/Esomeprazole Mag | D | $268K | -92% | 26 | $10,301 | $35.99 |
| Esomeprazole Sodium Esomeprazole Sodium | D | $31K | +24% | n/a | n/a | $20.35 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.